Clinical and Molecular Predictors of Response and Survival in Patients with Urothelial Carcinoma Treated with Enfortumab Vedotin: A Systematic Review and Meta-analysis

Background and objective: Enfortumab vedotin (EV) is emerging as a standard of care for advanced urothelial carcinoma (UC), but identification of which patients might benefit the most or least remains an unmet need. Our aim was to identify clinical and molecular parameters associated with EV sensiti...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Mohammed Altenni, Péter Fehérvári, Jakub Hoferica, Péter Hegyi, Nándor Ács, Tamás Fazekas, Judit Vargha, Viktor Grünwald, Christopher Darr, Péter Riesz, Péter Nyirády, Tibor Szarvas
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Elsevier 2025-12-01
سلاسل:	European Urology Open Science
الموضوعات:	Enfortumab vedotin NECTIN4 FGFR Immune checkpoint inhibitor Urothelial carcinoma Meta-analysis
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2666168325014417
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!